Project Grant R01HL180621
- The federal Project Grant award of $676,748.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will support research to extend neutrophil survival in neutropenia-related pneumonia. The goal is to explore an alternative strategy for treating and preventing neutropenia-related pneumonia by increasing the lifespan of neutrophils in the lungs of neutropenic patients. Specifically, the research will investigate the role and regulation of gasdermin D...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $759,983.00 to the University of North Carolina at Chapel Hill to conduct research on the role of neutrophils in lung infections and acute lung injury. The study aims to examine changes in neutrophil transcriptomes and function during Streptococcus pneumoniae pneumonia, with the goal of improving understanding of the lung's immune response and potential...
- This Project Grant award of $796,189.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at the University of Illinois to define the dynamics of neutrophil subpopulations and their role in inflammatory lung injury and repair. The study aims to identify the distinct functions of the CXCR2 and CXCR4 chemokine receptors in regulating neutrophil trafficking and activation during acute lung inflammation, with the goal of developing...
- This $136,050 Project Grant was awarded on June 30, 2025 by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, to Tufts University School of Medicine. The grant supports research to characterize lung resident B1 cells and their impact on lung homeostasis during development. The research aims to investigate the functional role of B1 cells in developing lungs and their contribution to maintaining lung homeostasis, which...
- This Project Grant award for $814,387 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is supporting research to investigate the role of a novel subpopulation of innate lymphoid cells (ILC3s) in lung infections and vascular regeneration. The award recipient, The Trustees of Columbia University, will utilize mouse models, single-cell analysis, and in vitro assays to: Define the tissue niche and response dynamics of lung vascular ILC3s (VILC3s),...
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $249,000.00 in funding to Brigham & Women's Hospital Inc. (a subsidiary of Partners Healthcare System) to develop methodologies for revealing the role of the blood microbiome in the gut-lung axis for asthma pathogenesis. The key products and services to be delivered include: A strain-resolved computational pipeline for reduced metagenomic sequencing to...
- The federal Project Grant award of $108,978.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the mechanisms underlying the age-related decline in the regenerative capacity of alveolar type 2 (AT2) cells in the lung. The principal investigator and research team at the Harvard T.H. Chan School of Public Health will conduct studies to determine whether elevated interferon gamma (IFNG) levels and changes in resident...
- This federal Project Grant award of $761,017.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to identify and characterize human pulmonary neuroendocrine progenitor cells (NEPRs) within the distal airways and their role in airway repair and injury response. The research aims to build a foundational understanding of the anatomical distribution, molecular profiles, and functional characteristics of these rare human lung cell...
- This federal Project Grant award, valued at $583,233.00 and awarded by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), aims to investigate the role of circulating osteopontin (OPN) and the CD44 receptor on innate immune cells in remote lung inflammation following acute kidney injury. The overall goal is to develop novel strategies to prevent or treat secondary organ complications in multi-organ failure. Key objectives include: 1) identifying lung...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $144,989 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop, train, and test deep generative models using computed tomography (CT) images to predict lung injury progression and treatment responses in patients with acute respiratory distress syndrome (ARDS). The goal is to leverage artificial intelligence and image...
This federal Project Grant award of $710,302 from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program aims to investigate the origin and characterize the functional state of the lung interstitial neutrophil (LIN) subset. The project seeks to advance the understanding of the function, fate, pathophysiological role, and origin of LINs, and explore their therapeutic potential. The research will be conducted by Brigham & Women's Hospital Inc., a subsidiary of the Partners Healthcare System (now Mass General Brigham), over a period from September 1, 2025 to May 31, 2029. The project will involve a multi-pronged approach to characterize the LIN population, including preliminary scRNA-seq analysis, transcriptional reprogramming studies, and exploring the specialized bactericidal properties and therapeutic potential of this neutrophil subset.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $710.3k | 8/21/25 |